Company
L'EQ Score indique l'activité et l'attractivité de l'entreprise sur la plateforme : complétude du profil, actualités, likes, follows, appartenance à un ou plusieurs labels ou communautés, nombre de membres de son réseau, etc.
Rius Medical mission is to make its proprietary highly innovative platform available at year 2 to pharmaceutical and biotech partners - Proprietary cell lines for drug delivery. Engineer stem cells for next generation therapeutics as core business.
Waldachtal, Baden-Württemberg, Germany
Send a message
Anglais
Anglais
The Elevator Pitch: Rius Medical is developing Advanced Manufacturing to help patients with cancer and other diseases, like type 1 diabetes by solving the problem of Drug Delivery through reprogramming stem cells.
On offer as Business-to-Business solution to France-based Erytech Pharma, Switzerland-based Orphan Technologies among others is upgraded red blood cells that do more than simply carry oxygen. For example...
The Elevator Pitch: Rius Medical is developing Advanced Manufacturing to help patients with cancer and other diseases, like type 1 diabetes by solving the problem of Drug Delivery through reprogramming stem cells.
On offer as Business-to-Business solution to France-based Erytech Pharma, Switzerland-based Orphan Technologies among others is upgraded red blood cells that do more than simply carry oxygen. For example Erytech Pharma’s therapeutic product (half-life 29 days) is undergoing clinical Phase III for pancreatic cancer and clinical Phase II for breast cancer. The Business Model is that of a provider/supplier of 120 days lifespan red blood cells against blood donation half-life 29 days red blood cells.
Rius Medical is seeking a 400,000 euro bridge financing for early start July 2021 onwards instead of December 2021 under EIC Pathfinder OPEN grant – supporting the exploration of bold ideas for radically new technologies. Rius Medical proposal has a convincing long-term vision of a radically new technology with a transformative positive effect to the economy and society.
An EXIT opportunity at year 2 for early investors joining this Series A investment round of up to 1 million euro and post-money valuation at 5 million euro will result in EUR 10,5 million financial benefits on TWO products at year 2. So 400,000 euro bridge financing against 8% ownership results in EUR 4,2 million financial benefits on TWO products by December 2022!
6
Followers
1
Like
Start in 31 August 2016
31 August 2016
registration with the commercial register of Stuttgart local court under folio HRB 757947
to be continued ...